Myriad Genetics Lowers FY2026 Sales Guidance from $860.000M-$880.000M to $770.000M-$790.000M vs $863.568M Est

Benzinga Newsdesk www.benzinga.com Negative 96.4%

Neg 96.4% Neu 0% Pos 0%

Myriad Genetics (NASDAQ:MYGN) lowers FY2026 sales outlook from $860.000 million-$880.000 million to $770.000 million-$790.000 million vs $863.568 million estimate.